Kainos Medicine Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 25
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Financing Rounds
  • 6
  • Investments
  • 1

Kainos Medicine General Information

Description

Kainos Medicine Inc is a clinical-stage company, researches and develops various medicines for cancers, and brain and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is under Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is under Phase II clinical study to treat HIV/AIDS.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 4F, Institut Pasteur Koea, 16
  • Daewangpangyo-ro 712beon-gil, Bundang-gu
  • Seongnam-si, Gyeonggi-do 13488
  • South Korea
+82 00-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kainos Medicine Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kainos Medicine‘s full profile, request access.

Request a free trial

Kainos Medicine Executive Team (10)

Name Title Board Seat Contact Info
Jason Rhee Chief Financial Officer
In Chull Kim Ph.D Chief Strategy Officer
Jaemoon Lee Ph.D Chief Business Officer & Vice President of Biology
Karl Kim Ph.D Chief Medical Officer
Kisub Lee Co-Founder, Chief Executive Officer & Chairperson
You’re viewing 5 of 10 executive team members. Get the full list »

Kainos Medicine Board Members (4)

Name Representing Role Since
000 0000 Kainos Medicine Independent Director 000 0000
000 000 Kainos Medicine Independent Director 000 0000
You’re viewing 2 of 4 board members. Get the full list »

Kainos Medicine Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kainos Medicine Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kainos Medicine‘s full profile, request access.

Request a free trial

Kainos Medicine Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 01-Aug-2020 00000 00000 00 0000 Drug Discovery
To view Kainos Medicine’s complete investments history, request access »